EQ News and Press, Equillium Inc. From 08/30/23

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host investor meetings at the Wells Fargo Healthcare Conference...

Revenue Increases Over 50% - EBITDA on Track to Profitability - New $4M Credit Facility TORONTO, ON / ACCESSWIRE / August 29, 2023 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in AI and geospatial data driven software and solutions, announced its financial results today for t...

2023-08-09 17:52:25 ET Equillium press release ( NASDAQ: EQ ): Q2 GAAP EPS of -$0.10 beats by $0.06 . Revenue of $9.12M beats by $2.98M . For further details see: Equillium GAAP EPS of -$0.10 beats by $0.06, revenue of $9.12M beats by $2.98M

$48.4 million in cash at the end of Q2 2023 expected to provide operating runway into 2025 Fully prepaid and retired debt facility Authorized $7.5 million stock repurchase program Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep...

2023-08-02 18:17:24 ET Clinical-stage biotech Equillium ( NASDAQ: EQ ) on Thursday said its board had approved a share buyback of up to $7.5M. EQ stock soared 32% to $0.99 after hours. "This repurchase program does not meaningfully affect our cash runway which remains ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that its Board of Directors authorized the repurchase of up to $7.5 million ...

2023-06-13 16:47:38 ET Equity Commonwealth's ( NYSE: EQC ) board on Tuesday authorized the office property REIT to repurchase up to $150M of its shares outstanding under a new stock buyback program. EQC stock gained 2.5% in Tuesday after-hours trading. The company'...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the Jefferies Global Healthcare Conference and the LD Micro Inv...

Continued Progress on Recurring Revenue, Increased Gross Margin and a Focus on Profitability TORONTO, ON / ACCESSWIRE / May 19, 2023 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in geospatial data and artificial intelligence driven software and solutions, announced its financi...

EQ102 selectively blocks IL-15 and IL-21 signaling while preserving signaling of other gamma chain family members Data suggest that selective blockade of IL-15 and IL-21 inhibits the synergistic signaling that mediates NK and T cell responses in multiple immune disorders including celiac ...